drugset / Trial / NCT00855166

Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

NCT00855166

Phase 3 Completed 182 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.

Timeline

Start
2009-02
Primary completion
2010-06
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Background Metformin Small molecule 1500 mg Oral
Background Metformin Small molecule 2500 mg Oral
Background Sitagliptin Small molecule 100 mg Oral